Human nasal mucosa cells

COVID-19: What is driving the escalating hyperinflammation

The severity of COVID-19 is primary result of a dysregulated immune response. A cellular stress response mechanism plays a major role in the derailed immune response: senescence, report Clemens Schmitt and his colleagues in “Nature“. This suggests novel treatment path.

Cellular senescence is a tissue-protective mechanism which is triggered in response to stress and injury. It results in the programmed cessation of cell division, thereby also protecting against cancer. Senescent cells release pro-inflammatory messengers which are important in wound healing. When present in excess or produced for too long, these inflammation modulators promote age-related diseases like diabetes and atherosclerosis. Sparse evidence that senescence may also be triggered by viral infections has, until now, received little attention.

A team of researchers from Charité – Universitätsmedizin Berlin, the Max-Delbrück-Center for Molecular Medicine (MDC), Johannes Kepler University (JKU) Linz and Kepler University Hospital (KUK) led by the oncologist Professor Clemens Schmitt has now shown in “Nature“ that this process plays a crucial role in triggering a veritable avalanche of inflammatory mediators, which contribute to the lung damage associated with COVID-19. Drugs capable of selectively eliminating senescent cells were shown to mitigate COVID-19-related lung damage in animal models, in addition to significantly reducing inflammation. “In our view, the early use of specific substances which disrupt this inflammatory overreaction holds enormous potential as a new treatment strategy for COVID-19,” says the cancer specialist.

Infection drives mucosal cells into senescence

In addition to his position as Director of the Molecular Cancer Research Center (MKFZ), Clemens Schmitt is Head of the MDC’s “Cancer Genetics and Cellular Stress Responses” research group and Research Group Lead at Charité’s Department of Hematology, Oncology and Tumor Immunology on Campus Virchow Klinikum. He is also the Head of Hematology/Oncology at the KUK and holds a professorship at the JKU Linz. Schmitt´s research into COVID-19 benefits from his long-standing expertise in the field of senescence, in particular as it pertains to cancer. Working alongside his team of researchers, he has been using both cell-based models and animal models to study the role of senescence in the body’s immune response to SARS-CoV-2 infection.

Human nasal mucosa cells which have started their senescence program in response to SARS-CoV-2 infection. The cells were stained using a standard test for evaluating senescence which produces a characteristic blue color.

In their article, the researchers show that the cellular stress-response program initiates an avalanche-like inflammatory response which culminates in the pneumonia typically seen in COVID-19. Simply put, the cascade begins inside SARS-CoV-2-infected cells of the upper respiratory tract, where viral entry into mucosal epithelial cells triggers a cellular stress response which activates their senescence program. Once senescent, the mucosal epithelial cells produce ample amounts of pro-inflammatory messengers. These, in turn, attract specific immune cells known as macrophages, which infiltrate the mucosa in order to remove senescent cells.

Due to the presence of the pro-inflammatory factors, however, the macrophages are themselves driven into the senescent state and release now large quantities of such factors themselves. Senescent macrophages can then infiltrate the lungs, where they may trigger senescence in other cells, such as the extremely sensitive cells lining the lung’s small blood vessels. Thrombogenic substances produced in response to this insult result in microthrombosis, i.e., the formation of tiny blood clots which obstruct the lung’s small blood vessels. Blood flow and oxygen exchange are severely impaired.

Interrupt the cascade early on

“The cellular stress program is an important driver of such escalating hyperinflammation which plays a major role in producing many of the characteristic features of COVID-19 pneumonia, such as vascular damage and microthrombosis,” explains the study’s first author, Dr. Soyoung Lee, a researcher based at the MDC and Charité’s Department of Hematology, Oncology and Tumor Immunology as well as the MKFZ on Campus Virchow Klinikum. “It was therefore a logical step to test whether we might be able to mitigate disease severity through early targeting of cells affected by virus-induced senescence.”

The team used animal models to study the effects of four distinct drugs which attack senescent cells in a targeted manner: navitoclax, fisetin, quercetin and dasatinib. Two of these senolytics are plant-based compounds; the other two are approved as or tested for cancer therapy. When used in hamsters and mice, all four substances – some used on their own, others in combination – achieved varying degrees of success in normalizing the hyperinflammation cascade and mitigating lung injury. The research team was able to refer to data from two smaller clinical studies which had already been completed. A combined analysis of the available data suggested that one of the senolytics tested was also able to reduce the risk of severe COVID-19 in humans.

Clinical studies test dose and side effects

Just like other therapeutic agents, however, senolytics can have side effects. Many questions therefore remain to be answered before we can consider them as a potential treatment against COVID-19.
Prof. Dr.  Clemens Schmitt
Clemens Schmitt Head of the Lab "Cancer Genetics and Cellular Stress Responses"

“These results are extremely encouraging,” says Schmitt, who also conducts research at the German Cancer Consortium (DKTK). He adds: “Just like other therapeutic agents, however, senolytics can have side effects. Many questions therefore remain to be answered before we can consider them as a potential treatment against COVID-19. For instance: what is the effective dose? At which point and for how long will these substances need to be administered? What side effects are associated with their use? Might older people derive more benefit from senolytics than younger patients? After all, aging is associated with an increase in the number of cells which are ready to enter senescence. This needs to be explored in further clinical studies, some of which are already underway in a number of institutions across the globe.”

While the researchers await the results of these clinical COVID-19 studies with great interest, they are also looking beyond the current pandemic. “Our study has shown that different types of cells initiate senescence not only in response to an infection with SARS-CoV-2, but also in response to other viruses,” explains Lee. “Our hope is therefore that our findings will be of relevance to other infectious diseases in which the body’s immune response plays a crucial role in determining disease severity.”

A joint press release by Charité, the MDC, JKU Linz and the Kepler University Hospital

 

Further information

 

Literature

Lee S, Yong Y et al. (2021): „Virus-induced senescence is driver and therapeutic target in COVID-19“. Nature, DOI: 10.1038/s41586-021-03995-1

 

Photo to download

Human nasal mucosa cells which have started their senescence program in response to SARS-CoV-2 infection. The cells were stained using a standard test for evaluating senescence which produces a characteristic blue color. Photo: Charité | Soyoung Lee

 

Contacts

Prof. Dr. Clemens Schmitt
Head of the Lab “Cancer Genetics and Cellular Stress Responses”
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
Charité – Universitätsmedizin Berlin (CVK)
+49 30 450 553 292
clemens.schmitt@charite.de

Jana Schlütter
Editor, Communications Department
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
+49 30 9406 2121
jana.schluetter@mdc-berlin.de or presse@mdc-berlin.de

 

Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)

 

The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) is one of the world’s leading biomedical research institutions. Max Delbrück, a Berlin native, was a Nobel laureate and one of the founders of molecular biology. At the MDC’s locations in Berlin-Buch and Mitte, researchers from some 60 countries analyze the human system – investigating the biological foundations of life from its most elementary building blocks to systems-wide mechanisms. By understanding what regulates or disrupts the dynamic equilibrium in a cell, an organ, or the entire body, we can prevent diseases, diagnose them earlier, and stop their progression with tailored therapies. Patients should benefit as soon as possible from basic research discoveries. The MDC therefore supports spin-off creation and participates in collaborative networks. It works in close partnership with Charité – Universitätsmedizin Berlin in the jointly run Experimental and Clinical Research Center (ECRC ), the Berlin Institute of Health (BIH) at Charité, and the German Center for Cardiovascular Research (DZHK). Founded in 1992, the MDC today employs 1,600 people and is funded 90 percent by the German federal government and 10 percent by the State of Berlin.